JP Morgan Chase
TFFP

JP Morgan Chase’s TFF Pharmaceuticals, Inc. Common Stock TFFP Stock Holding History

JP Morgan Chase’s Portfolio TFFP Stock Details TFFP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5
Closed -$31 – 7820
2024
Q1 		$31 Sell
5
-1,065
-100% -$6.97K ﹤0.01% 7113
2023
Q4 		$7.51K Buy
1,070
+1,068
+53,400% +$8.3K ﹤0.01% 6480
2023
Q3 		$21 Buy
+2
New +$19 ﹤0.01% 7162
2022
Q3 		– Sell
-1,725
Closed -$244K – 6944
2022
Q2 		$244K Sell
1,725
-103
-6% -$14.4K ﹤0.01% 4971
2022
Q1 		$288K Sell
1,828
-744
-29% -$120K ﹤0.01% 4989
2021
Q4 		$570K Sell
2,572
-540
-17% -$104K ﹤0.01% 4744
2021
Q3 		$601K Buy
3,112
+2,812
+937% +$597K ﹤0.01% 4622
2021
Q2 		$72K Buy
300
+220
+275% +$60.3K ﹤0.01% 5641
2021
Q1 		$27K Buy
+80
New +$32.5K ﹤0.01% 5659
2020
Q4 		– Hold
0
– – – 5997
2020
Q3 		– Hold
0
– – – 5851
2020
Q2 		– Hold
0
– – – 5765

Other funds holding TFFP

CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $1.74B AUM 32.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase's TFFP Position: Q2 2024 in Review

JP Morgan Chase sold out of TFF Pharmaceuticals, Inc. Common Stock (TFFP) in Q2 2024, closing a stake of 5 shares — an estimated $31 sold.

JP Morgan Chase first reported a position in TFFP in Q1 2021 and held it in 9 quarters. The position peaked at $601K in Q3 2021. 21 funds tracked by Wall St. Rank hold TFFP as of Q2 2024.

  • JP Morgan Chase reported no remaining TFF Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • JP Morgan Chase sold 5 TFF Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $31.
  • JP Morgan Chase first reported a position in TFF Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • JP Morgan Chase's TFF Pharmaceuticals, Inc. Common Stock position peaked at $601K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held TFF Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.